How often to repeat an extended blood test, and what it can and cannot measure

An extended blood test is a panel of roughly 40 to 100 analytes drawn in one sitting.

• a CBC with differential
• a comprehensive metabolic panel
• a lipid panel with particle counts or ApoB
• HbA1c
• thyroid function
• iron studies
• a handful of hormones
• a few inflammatory markers
• some vitamins

It is not a test that checks everything. Human plasma contains thousands of proteins spanning ten orders of magnitude in concentration, and a clinical panel samples a few dozen of them chosen because they have validated assays and decision thresholds. For most healthy adults, drawing blood two days in a row is safe, and the real constraint on repeat testing is not blood volume but biology: most analytes do not move fast enough for a second draw a week later to tell you anything a single draw did not.

Assay economics limits the panel, and biology does not

Every analyte on a clinical panel needs a validated assay, a traceable calibrator, a reference interval, and a billing code. That filter removes almost everything interesting and leaves the things that are cheap to measure at high throughput on an immunoassay or chemistry analyzer. Ordering more of them does not close the gap. A protein has to be abundant enough in plasma, specific enough to a process, and stable enough in a tube to be useful.

The abundance problem is worth understanding quantitatively, because it sets a hard floor on what a blood panel can catch early. Modeling of tumor-derived biomarker shedding into plasma shows that for a marker secreted at plausible rates and cleared at plausible rates, a tumor must reach a substantial size before its contribution rises above the healthy inter-individual background, which is why single-marker blood screening for early cancer performs poorly no matter how sensitive the assay is.¹ Combining markers helps: antibody panels built from several analytes outperform any single one for breast cancer discrimination.² That is the general shape of the answer. Panels beat singletons, and even good panels have a detection floor set by dilution into five liters of plasma.

The analytes we would order

Group them by what question they answer and by how fast they move. This matters more than the vendor’s marketing categories.

Slow, integrative markers change over months.

• HbA1c
• ApoB
• Lp(a) (measure once, it is largely genetic)
• ferritin plus transferrin saturation
• TSH with free T4
• creatinine and cystatin C for two independent eGFR estimates

Lp(a) is the clearest case for a single lifetime measurement. Repeating it annually is wasted money.

Medium-speed markers change over weeks.

• CBC indices
• vitamin D 25-OH
• homocysteine
• ALT/AST/GGT
• fasting insulin

Red cell parameters carry a built-in clock, since MCV and reticulocyte counts respond over the ~120-day erythrocyte lifespan.

Fast, noisy markers change over hours to days.

• hs-CRP
• IL-6
• cortisol
• testosterone
• glucose
• triglycerides

These have within-subject coefficients of variation large enough that a single value is close to uninformative. Daily-diary work shows that negative affect on the day of the draw and in the preceding days predicts circulating inflammatory markers, with the timing of the affect mattering for which marker moves.³ If you had a bad week, your CRP knows.

Markers with a defined detection window: alcohol biomarkers are the cleanest teaching example. Phosphatidylethanol, CDT, GGT, and MCV each reflect a different exposure window from days to weeks, and interpreting any one of them without knowing its window produces nonsense.⁴

Reference change value is the number that decides if a delta is real

Before comparing two draws, compute the reference change value:

RCV = Z * sqrt(2) * sqrt(CVa^2 + CVi^2)

CVa is the lab’s analytical CV for that assay (ask for it, or take it from their method validation sheet), CVi is the published within-subject biological CV, and Z is 1.96 for a two-sided 95% call.

For HbA1c, with CVa and CVi both around 2%, RCV lands near 8% relative. A move from 5.4% to 5.6% is inside noise. For hs-CRP, CVi is commonly reported above 40%, which pushes RCV past 100%. A doubling of CRP between two draws is not evidence of anything by itself. A single calculation like this will kill most of the “my marker changed” stories people tell themselves from consecutive panels.

Assay platform changes cause the other big class of false signals. Different manufacturers’ immunoassays for the same protein return different absolute values and use different cutoffs, a problem documented in detail for traumatic brain injury markers where cross-platform comparability remains unresolved.⁵ If your lab switches vendors between draws, you have a step change in the data that has nothing to do with you. Record the assay method and analyzer with every result.

Draw spacing, and why two days in a row is fine

An extended panel is typically 6 to 10 tubes, 30 to 60 mL total. Adult blood volume runs about 70 mL/kg, so roughly 5 L in a 70 kg person. A 50 mL draw is about 1% of that, and plasma volume is restored within a day. Commonly used research volume limits for adults sit in the range of 550 mL over any 8-week period, which is far above what repeat panels consume. The constraint on back-to-back draws is the vein and the person. It is not the volume.

What changes with spacing is information. We would run a full extended panel every 6 to 12 months, and use short-interval repeats only for two purposes:

1. Confirming a single out-of-range fast marker before acting on it. Repeat in 1 to 2 weeks, same time of day, same fasting state.
2. Deliberate within-subject variance estimation. Three to five draws over two weeks under matched conditions gives you a personal CVi for your noisy analytes, which makes every future comparison sharper. This is the highest-value unusual thing you can do with a lab account.

Timing relative to an event matters as much as interval length. In the TRACK-TBI cohort, blood biomarker levels after head injury depend jointly on age and on time since injury, so a value is only interpretable against the clock.⁶ The same logic applies to exercise, illness, and travel. A panel drawn 36 hours after a hard session measures the session.

If a result is flagged critical, or you have symptoms, that is a clinician’s call and not a data problem. Do not self-manage abnormal results.

Get the data out in a computable form

Most portals hand you a PDF. Do not build on PDFs. Ask for one of these, in order of preference:

• FHIR R4 Observation resources as JSON, with LOINC in code.coding, UCUM units in valueQuantity.code, and effectiveDateTime for collection time. Parse with fhir.resources in Python.
• HL7 v2.5.1 ORU^R01 messages, pipe-delimited. The LOINC code is in OBX-3, the value in OBX-5 and the units in OBX-6. The reference range is in OBX-7 and the collection datetime in OBX-14. Segment parsing is handled by hl7apy.
• A CSV export, which will lack LOINC codes and force you to map analyte names by hand once per lab.

Store everything long, one row per measurement, as Parquet:

subject_id, loinc, analyte, value, unit, ref_low, ref_high,
collected_at, fasting_hours, assay_method, analyzer, lab_id, specimen_type

Normalize units at ingest (ferritin in ng/mL vs µg/L is a free 1:1, testosterone in ng/dL vs nmol/L is not). Keep the raw value and the normalized value in separate columns so you can audit conversions later. Plot every analyte against collected_at with its personal RCV band. Do not use the population reference interval for the band. The reference interval tells you where 95% of a reference population sits. The RCV band tells you when you moved.

Questions people also ask

Is it okay to have blood drawn two days in a row? For a healthy adult, yes. Two extended panels is on the order of 100 mL total against a blood volume near 5 L. The practical limits are vein irritation and bruising, so alternate arms. Anyone with anemia, low body weight, a bleeding disorder, or an active illness should ask a clinician first.

How long should you wait in between blood draws? Match the interval to the analyte’s biology. Two weeks for fast markers like hs-CRP or testosterone, and 3 months for HbA1c. Shorter than that and you are re-measuring the same red cells. Allow 6 to 12 months for a full extended panel, and measure Lp(a) once ever.

Does a regular blood test check for everything? No. A standard CMP plus CBC is about 25 analytes. An extended panel is 40 to 100. Plasma holds thousands of measurable proteins, and dilution sets a floor on what low-abundance markers can reveal, which is the central reason single-marker blood screening for early cancer underperforms.¹

How many blood tests can you have in a week? Volume-wise, several extended panels per week stay well inside standard research limits for adults. Information-wise, more than one per week is usually noise unless you are deliberately estimating your own within-subject variation.

Can you get a blood test that checks everything? No single test does. Research assays are pushing the boundary in both directions: multiplexed nanoelectronic sensors can read several protein markers from an intradermal prick without a venous draw,⁷ and marker sets for conditions like Long COVID keep expanding as new pathways are implicated.⁸ Neither replaces a panel chosen to answer specific questions about you.

Footnotes

1. Sharon S. Hori, Sanjiv S. Gambhir. Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations. Science Translational Medicine, 2011. https://doi.org/10.1126/scitranslmed.3003110 ↩ ↩²

2. Galit Yahalom, Daria Weiss, Ilya Novikov, et al. An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomarkers in Cancer, 2013. https://doi.org/10.4137/bic.s13236 ↩

3. Jennifer E. Graham‐Engeland, Nancy L. Sin, Joshua M. Smyth, et al. Negative and positive affect as predictors of inflammation: Timing matters. Brain Behavior and Immunity, 2018. https://doi.org/10.1016/j.bbi.2018.09.011 ↩

4. Julia C. Harris, Lorenzo Leggio, Mehdi Farokhnia. Blood Biomarkers of Alcohol Use: A Scoping Review. Current Addiction Reports, 2021. https://doi.org/10.1007/s40429-021-00402-7 ↩

5. Daniel B. Hier, Tayo Obafemi-Ajayi, Matthew S. Thimgan, et al. Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues. Biomarker Research, 2021. https://doi.org/10.1186/s40364-021-00325-5 ↩

6. Raquel C. Gardner, Ava M. Puccio, Frederick K. Korley, et al. Effects of age and time since injury on traumatic brain injury blood biomarkers: a TRACK-TBI study. Brain Communications, 2022. https://doi.org/10.1093/braincomms/fcac316 ↩

7. Nimrod Harpak, Ella Borberg, Adva Raz, et al. The “Bloodless” Blood Test: Intradermal Prick Nanoelectronics for the Blood Extraction-Free Multiplex Detection of Protein Biomarkers. ACS Nano, 2022. https://doi.org/10.1021/acsnano.2c01793 ↩

8. Maitray A. Patel, Michael J. Knauer, Michael Nicholson, et al. Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Molecular Medicine, 2022. https://doi.org/10.1186/s10020-022-00548-8 ↩